

Concept Reminder: TARGETED DESTRUCTION OF SENESCENT CELLS IN CANCER

StarkAge Therapeutics is a biotechnology company dedicated to combating cellular senescence in various age-related pathologies.

Main Program: CANCER

Our approach enhances the effectiveness and reduces the side effects of chemotherapy and radiotherapy by selectively destroying senescent cells induced by these treatments.

Lead Drug Candidate: STX-1

An armed monoclonal anti-DPP4 antibody (ADC) designed to specifically target cancerous senescent cells.

Patent granted in the United States in June 2023.

Seed Fundraising: €3M Ongoing

We hope to convince you to join us for this round!

www.starkagetx.com

Newsletter #6

Dear Partners and Future Partners,

In recent months, StarkAge Therapeutics has achieved remarkable milestones. Exceptional results in the efficacy and safety of STX-1, combined with a strengthened governance, have propelled us into a new phase of growth. These accomplishments would not have been possible without our successful fundraising earlier this year. We extend our sincere gratitude to our new shareholders for their trust and support.

1. CORPORATE UPDATES:

➤ **Leadership Transition**

Dr. Thierry Mathieu, Founder and President of StarkAge Therapeutics, **has entrusted the role of Chief Executive Officer (CEO) to Dr. Benjamin Le Calvé**, formerly Chief Scientific Officer (CSO), effective September 30, 2024.

This transition marks a pivotal moment for StarkAge, now well-positioned to achieve its strategic goals. Dr. Le Calvé, a talented and proven leader, brings a dynamic vision and unwavering commitment to driving our project forward. We are deeply grateful for his acceptance of this role and confident in his ability to guide StarkAge to

success.

➤ **Strengthened Strategic Committees**

Our Advisory Board (future Board of Directors) and Scientific Advisory Board (SAB) have been reinforced with leading experts.

Advisory Board

This strategic committee supports our development with experts in biotech financing, complex project management, and international expansion:

- **François Descamps**: Engineer and representative of Northern France Business Angels.
- **Georges Lotigier**: Serial entrepreneur and expert in intellectual property and international development.
- **Dr. Laurent Jacquaroud**: Biotech financing specialist and former partner at Kurma Partners.
- **Dr. Florence Lhospice**: Fundraising and Chemistry, Manufacturing and Controls (CMC) expert, former director at Emergence Therapeutics.
- **Dr. Laurent Metz**: Harvard-trained physician and biotech strategist.
- **Cédric Mathieu**: TURO Canada Comex member with expertise in international partnerships

Scientific Advisory Board

StarkAge's SAB includes global leaders in aging biology and oncology:



- **Dr. Éric Angevin (Gustave Roussy)**: Renowned oncologist, expert in monoclonal antibodies and immunotherapy, with over 300 clinical trials conducted.
- **Prof. Cléo Bishop (Queen Mary University of London)**: Specialist in cellular senescence, pioneering biomarker research like p16.
- **Dr. David Bernard (CRCL, Lyon)**: Expert in senescence and carcinogenesis mechanisms, research director at CNRS.
- **Dr. Fabrizio d'Adda di Fagagna (IFOM, Milan)**: Authority on telomeres and cellular aging, recipient of multiple international awards.
- **Prof. Michail Ignatiadis (Institut Jules Bordet, Belgium)**: Breast cancer oncologist and EORTC research group president.

These distinguished experts play a central role in shaping our scientific strategy and accelerating our research programs.



2. SCIENTIFIC ACHIEVEMENTS :

- **In vivo studies on STX-1 have demonstrated efficacy surpassing expectations across multiple cancer types.**

HepG2: Hepatocarcinoma model




LoVo: Colon Adenocarcinoma model



- Toxicity studies have shown **remarkable tolerance**, even at doses 10 times higher than therapeutic levels.

Single dose injection at 25, 50 and 100mg/kg



Next Objectives:

- Expand efficacy studies to other cancers (colon, esophagus, pancreas, stomach, kidney, thyroid).
- Optimize STX-1 by humanizing our patented antibody.
- Broaden our patent portfolio.
- Advance the development of our second drug candidate, STX-2.

3. UPCOMING FUNDRAISING

We have initiated our Road Show to secure **€3M in Seed funding**, targeting closure between Q1 and Q2 2025.

Objectives for this round:

- Finalize the preclinical development of STX-1 and submit the application for Phase 1 clinical trials in humans.
- Expand our pipeline with the development of STX-2 and STX-3.

Funding Needs:

- **€2M in dilutive funds** (family offices and VCs).
- **€1M in non-dilutive funds** (i-Nov grants and banking partners) to support activities through 2026.

For further information, please contact:

Thierry Mathieu
President
thierry.mathieu@starkage.com
+33.6.77.17.72.27